Contemporary Pharmacotherapy for OAB 2024: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2024)

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation, and innovation. The updated AUA/SUFU (Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction) Guideline on the diagnosis and treatment of overactive bladder (nonneurogenic) in adults as well as the recently published proceedings of the 7th International Consultation on Incontinence have maintained considerable interest in this area among researchers and practitioners. This course will outline the new AUA/SUFU Guideline, describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder, review currently available agents and discuss agents in development.


This educational activity is supported by independent educational grants from:


Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)
  2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.
  3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB
  4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents
  5. Discuss potential future pharmacological pathways and therapies for OAB.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Rovner, Eric ScottAllerganConsultant or AdvisorCurrent
MedtronicsConsultant or Advisor10/01/2023
UrovantScientific Study or TrialCurrent
BluewindConsultant or AdvisorCurrent
HologixConsultant or Advisor11/01/2023
uromedicaScientific Study or Trial04/04/2023
ValenciaConsultant or Advisor10/01/2023
AvationConsultant or Advisor10/01/2023
Boston ScientificMeeting Participant or Lecturer10/01/2023
AxonicsConsultant or Advisor04/02/2024
IronwoodScientific Study or Trial04/02/2024
Synapse ICConsultant or AdvisorCurrent
ViveveConsultant or Advisor04/04/2023
UrocureStock OptionCurrent
Smith, Ariana L.No relevant financial relationships to disclose
Wein, Alan JeromeUrovantConsultant or AdvisorCurrent



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.